We are live on ! Find out more
TERN

Terns Pharmaceuticals
TERN

Delisted

TERN was delisted on the 4th of May, 2026.

Back to rankings

78 hedge funds and large institutions have $630M invested in Terns Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 26 increasing their positions, 15 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

93% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 14

73% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 15

40% more funds holding in top 10

Funds holding in top 10: 5 → 7 (+2)

25% more capital invested

Capital invested by funds: $505M → $630M (+$125M)

20% more funds holding

Funds holding: 65 → 78 (+13)

9.78% less ownership

Funds ownership: 103.68% → 93.9% (-9.8%)

Holders
78
Holders Change
+13
Holders Change %
+20%
% of All Funds
1.24%
Holding in Top 10
7
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+40%
% of All Funds
0.11%
New
27
Increased
26
Reduced
15
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
B
Braidwell
Connecticut
+$19.1M
2
PA
Perceptive Advisors
New York
+$12.9M
3
Franklin Resources
Franklin Resources
California
+$6.76M
4
Invesco
Invesco
Georgia
+$5.49M
5
BlackRock
BlackRock
New York
+$3.83M

Top Sellers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
-$10.2M
2
DM
Deerfield Management
New York
-$7.57M
3
PVI
Pura Vida Investments
New York
-$6.16M
4
AC
Armistice Capital
New York
-$5.7M
5
JP Morgan Chase
JP Morgan Chase
New York
-$5.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$3.61M +$1.21M +127,068 +72%
Dimensional Fund Advisors
27
Dimensional Fund Advisors
Texas
$2.81M +$1.32M +138,171 +140%
SB
28
Samsara BioCapital
California
$2.4M – – –
Marshall Wace
29
Marshall Wace
United Kingdom
$2.19M +$1.42M +148,947 +413%
Jane Street
30
Jane Street
New York
$1.77M +$1.22M +127,854 +594%
HS
31
HighVista Strategies
Massachusetts
$1.74M +$664K +69,510 +90%
Morgan Stanley
32
Morgan Stanley
New York
$1.68M +$1.18M +123,878 +686%
EI
33
EAM Investors
California
$1.52M – – –
BFM
34
Boothbay Fund Management
New York
$1.51M +$16K +1,670 +1%
VCIM
35
Velan Capital Investment Management
Georgia
$1.42M +$1.05M +109,354 +1,027%
State Street
36
State Street
Massachusetts
$1.41M +$569K +59,502 +100%
SSA
37
Schonfeld Strategic Advisors
New York
$1.36M +$1.1M +115,252 New
Renaissance Technologies
38
Renaissance Technologies
New York
$1.25M -$92.7K -9,700 -8%
PAMP
39
Polar Asset Management Partners
Ontario, Canada
$1.18M – – –
IHAM
40
Integral Health Asset Management
New York
$1.18M +$956K +100,000 New
Goldman Sachs
41
Goldman Sachs
New York
$1.06M +$750K +78,474 +725%
PHP
42
Parkman Healthcare Partners
Connecticut
$888K +$717K +75,000 New
Northern Trust
43
Northern Trust
Illinois
$652K +$224K +23,486 +74%
AI
44
Atom Investors
Texas
$615K +$496K +51,951 New
Qube Research & Technologies (QRT)
45
Qube Research & Technologies (QRT)
United Kingdom
$603K +$386K +40,406 +383%
BCM
46
Bridgeway Capital Management
Texas
$600K -$401K -42,000 -45%
Royal Bank of Canada
47
Royal Bank of Canada
Ontario, Canada
$592K +$476K +49,822 +27,375%
Bank of America
48
Bank of America
North Carolina
$568K +$441K +46,136 +2,542%
D.E. Shaw & Co
49
D.E. Shaw & Co
New York
$554K +$447K +46,762 New
Citigroup
50
Citigroup
New York
$537K -$6.26K -655 -1%
1
2
3 4

TERN Hedge Fund Activity: Q1 2023 in Review

78 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Terns Pharmaceuticals (TERN) for Q1 2023, worth a combined $630M — up 25% from $505M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new TERN positions and 14 closed out — a net gain of 13 holders — while 26 added to existing stakes and 15 trimmed.

The largest buyer was Braidwell, opening a new position worth an estimated $19.1M. The largest seller was RTW Investments, exiting entirely with an estimated $10.2M sold.

  • 78 institutional investors held Terns Pharmaceuticals (TERN) as of Q1 2023, up from 65 in Q4 2022.
  • Funds reported $630M of Terns Pharmaceuticals stock for Q1 2023, up 25% quarter-over-quarter.
  • 27 funds opened new Terns Pharmaceuticals positions in Q1 2023 and 14 closed out, a net change of +13 holders.
  • The largest Terns Pharmaceuticals buyer in Q1 2023 was Braidwell, an estimated $19.1M added.
  • The largest Terns Pharmaceuticals seller in Q1 2023 was RTW Investments, an estimated $10.2M sold.

Based on aggregated 13F filings for Q1 2023.